Reis-Neto, Edgard Torres dos http://orcid.org/0000-0003-0657-4825
Seguro, Luciana Parente Costa http://orcid.org/0000-0003-0538-9476
Sato, Emília Inoue http://orcid.org/0000-0001-8540-014X
Borba, Eduardo Ferreira http://orcid.org/0000-0001-6194-5129
Klumb, Evandro Mendes http://orcid.org/0000-0001-9546-3144
Costallat, Lilian Tereza Lavras http://orcid.org/0000-0002-3077-9479
Medeiros, Marta Maria das Chagas http://orcid.org/0000-0002-0389-8421
Bonfá, Eloisa http://orcid.org/0000-0002-0520-4681
Araújo, Nafice Costa http://orcid.org/0000-0002-9994-7311
Appenzeller, Simone http://orcid.org/0000-0001-5075-4474
Montandon, Ana Carolina de Oliveira e Silva http://orcid.org/0000-0001-5669-2542
Yuki, Emily Figueiredo Neves http://orcid.org/0000-0001-8801-405X
Teixeira, Roberto Cordeiro de Andrade http://orcid.org/0000-0002-4824-0543
Telles, Rosa Weiss http://orcid.org/0000-0003-4027-2943
Egypto, Danielle Christinne Soares do http://orcid.org/0000-0002-8236-024X
Ribeiro, Francinne Machado http://orcid.org/0000-0003-0038-983X
Gasparin, Andrese Aline http://orcid.org/0000-0001-7786-9562
Junior, Antonio Silaide de Araujo http://orcid.org/0000-0002-9352-9477
Neiva, Cláudia Lopes Santoro http://orcid.org/0000-0001-7964-990X
Calderaro, Debora Cerqueira http://orcid.org/0000-0001-5535-3223
Monticielo, Odirlei Andre http://orcid.org/0000-0003-0720-2097
Funding for this research was provided by:
Sociedade Brasileira de Reumatologia
Article History
Received: 16 April 2024
Accepted: 25 May 2024
First Online: 18 June 2024
Declarations
:
: Not applicable.
: Not applicable.
: The authors declare that the research was carried out in the absence of any commercial or financial relationship that could be interpreted as a potential conflict of interest. Several authors of these guidelines, including voting members, have interacted with the pharmaceutical industry including the manufacturers of some of the drugs mentioned in these recommendations. However, none of the authors received any support or fee directly or indirectly related to or influencing the development of these guidelines. ETRN received speaker fees and/or consultancies from AstraZeneca, GSK and Novartis and participate in clinical research from Abbvie, BMS and Novartis. LPCS received speaker and research fees from AstraZeneca and GSK and participate in clinical research from Abbvie, AstraZeneca, BMS, GSK and Novartis. EIS declares no competing interests. EFB declares no competing interests. EMK received speaker fees and/or consultancies and/or advisory boards from AstraZeneca and GSK. LTLC declares no competing interests. MMCM declares no competing interests. NCA received speaker fees, advisory boards and research fee from AstraZeneca and GSK and speaker fees from Organon. SA received speaker fees from AstraZeneca and GSK; ISS from GSK. ACOSM received speaker fees from AstraZeneca and GSK. EFNY received speaker fees from AstraZeneca. RCAT declares no competing interests. RWT declares no competing interests. DCSE received speaker fees and/or consultancies from Abbvie, AstraZeneca, Janssen and GSK. FMR received speaker fees/advisory boards from GSK and AstraZeneca. AAG declares no competing interests. ASAJ received speaker fees from GSK and AstraZeneca. CLSN received speaker fees from AstraZeneca and GSK, advisory boards from AstraZeneca and participate in clinical research from Abbvie, AstraZeneca, BMS, GSK, Lilly, Merck, Novartis, Pfizer, Roche and UCB. DCC received speaker and research fees from AstraZeneca and GSK and participate in clinical research from BMS, Novartis and Roche. OAM received speaker fees and/or consultancies and/or advisory boards from Abbvie, Astrazeneca, BMS, Celltrion, GSK, Janssen-Cilag, Novartis-Sandoz and UCB.